belong to a large family of cytoplasmic sensors that regulate an extraordinarily diverse range of biological functions. One of these functions is to contribute to immunity against infectious diseases, but dysregulation of their functional activity leads to the development of inflammatory and autoimmune diseases 1 . Cytoplasmic innate immune sensors, including NLRs, are central regulators of intestinal homeostasis 2-9 . NLRC3 (also known as CLR16.2 or NOD3) is a poorly characterized member of the NLR family and was identified in a genomic screen for genes encoding proteins bearing leucine-rich repeats (LRRs) and nucleotide-binding domains 10,11 . Expression of NLRC3 is drastically reduced in the tumour tissue of patients with colorectal cancer compared to healthy tissues 12 , highlighting an undefined potential function for this sensor in the development of cancer. Here we show that mice lacking NLRC3 are hyper-susceptible to colitis and colorectal tumorigenesis. The effect of NLRC3 is most dominant in enterocytes, in which it suppresses activation of the mTOR signalling pathways and inhibits cellular proliferation and stem-cell-derived organoid formation. NLRC3 associates with PI3Ks and blocks activation of the PI3K-dependent kinase AKT following binding of growth factor receptors or Toll-like receptor 4. These findings reveal a key role for NLRC3 as an inhibitor of the mTOR pathways, mediating protection against colorectal cancer.
* P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001; NS, not statistically significant by oneway ANOVA (a, g-i) or twotailed ttest (c, f). Data are from three (a-f) or two independent experiments (g-i) and are presented as mean ± s.e.m. in a, c, f-i.
All Nlrc3 −/− mice suffered highgrade dysplasia, whereas wildtype mice suffered lowgrade dysplasia (Extended Data Fig. 1e ). We found that 63% of the Nlrc3 −/− mice were positive for adenocarcinoma in the colon, compared to 0% of the wildtype controls at day 80 (Extended Data Fig. 1f ). Although NLRC3 showed a genedosedependent response to azoxymethane and DSS ( Fig. 1g ), it does not appear to have an effect on the normal mouse intestine or colon (Extended Data Fig. 1g ). Nlrc3 −/− mice lost significantly more body weight and suffered more severe shortening of, and damage to, the colon after only a single round of DSS treatment compared to their wildtype counterparts (Extended Data Fig. 2a -c). Certain members of the NLR protein family can form inflammasomes, driving maturation of IL18, a cytokine important for mediating protection against colitisassociated tumorigenesis [2] [3] [4] 15 . We did not observe differential production of IL18 in wildtype and Nlrc3 −/− mice at day 14 or at day 80 (Extended Data Fig. 2d ). Instead, production of the other inflammasomeassociated cytokine IL1β and inflammasomeindependent cytokines IL6, TNF and GCSF and the chemokines KC (also known as CXCL1), MCP1 (also known as CCL2) and MIP1α (also known as CCL3) was elevated in colon tissue of Nlrc3 −/− mice compared to wildtype mice at day 14 (Extended Data Fig. 2d -g). We further confirmed these results and also found increased levels of circulating IL6, GCSF, KC and MIP1α in the sera of Nlrc3 −/− mice compared to wildtype mice at day 14 (Extended Data Fig. 2h ). The expression of IL17 and IL22 was also elevated in the colon tissue of Nlrc3 −/− mice compared to wildtype mice at day 14, whereas the expression of IL23, IFNβ and IFNγ remained unchanged (Extended Data Fig. 3a ). Consistent with the observation that Nlrc3 −/− mice had elevated levels of many proinflammatory mediators at day 14, we observed increased levels of Iκ Bα and STAT3 phosphorylation in the colon tissue of Nlrc3 −/− mice compared to wildtype mice (Extended Data Fig. 3b ). However, differential phosphorylation of ERK was not observed (Extended Data Fig. 3b ). Global increases in the pro duction of inflammatory mediators and the activation of immune signalling pathways reflected the hypersusceptibility of Nlrc3 −/− mice to colitis.
Using flow cytometry, we profiled the immune cell populations in the colons of untreated wildtype and Nlrc3 −/− mice and wildtype and Nlrc3 −/− mice at days 8 and 14. We observed an increased number of macrophages, neutrophils and natural killer cells in the colons of Nlrc3 −/− mice compared to wildtype mice 14 days after azoxymethane and DSS treatment (Extended Data Fig. 3c, d) , which is consistent with the increased levels of inflammation observed at this time point. However, we did not observe differences in the relative number of macrophages, CD11b + CD11c + cells, neutrophils, B cells, CD4 + T cells, CD8 + T cells and natural killer cells between untreated wildtype and Nlrc3 −/− mice or mice at day 8 (Extended Data Fig. 3d ). NLRC3 has been implicated in the regulation of Tcell activation 11 ; however, we did not observe a difference in the levels of IFNγ + or TNF + CD4 + T cells when wildtype and Nlrc3 −/− splenocytes were stimulated with CD3 and CD28 in the presence of IL2 (Extended Data Fig. 3e ).
We performed bonemarrow chimaera studies to identify the contri bution of NLRC3 in haematopoietic cells versus radioresistant stromal cells during colitisassociated tumorigenesis. As we expected, Nlrc3 −/− mice that received Nlrc3 −/− bone marrow were more susceptible to tumorigenesis than wildtype mice that received wildtype bone mar row ( Fig. 1h and Extended Data Fig. 4a ). However, Nlrc3 −/− mice that received wildtype bone marrow had a significantly increased tumour burden compared with wildtype mice that received wildtype bone marrow. In addition, wildtype mice that received Nlrc3 −/− bone mar row had a significantly increased tumour burden compared to wildtype mice that received wildtype bone marrow ( Fig. 1h and Extended Data Fig. 4a ). We further confirmed our findings and generated mice that lacked NLRC3 in haematopoietic cells specifically (Vav1 cre Nlrc3 fl/fl ), cells of the myeloid lineage (LysM cre Nlrc3 fl/fl ) and intestinal epithelial cells (Vil1 cre Nlrc3 fl/fl ). Mice lacking NLRC3 in intestinal epithelial cells developed the highest number of tumours, followed by mice lacking NLRC3 in haematopoietic cells ( Fig. 1i and Extended Data Fig. 4b ).
Mice lacking NLRC3 in cells of the myeloid lineage had a similar number of tumours to wildtype mice ( Fig. 1i and Extended Data Fig. 4b ). These data support the observation that the oncogenic inhibi tory effect of NLRC3 is more dominant in intestinal epithelial cells and more subtle in haematopoietic cells.
A closer examination of the intestinal epithelial cells of Nlrc3 −/− mice revealed a significant increase in numbers of both Ki67 + and PCNA + (both proteins that are associated with cellular proliferation) cells per intestinal crypt compared to wildtype mice at day 14 ( Fig. 2a ). Additionally, colonic epithelial stem cells collected from Nlrc3 −/− mice more readily developed into organoids in ex vivo culture compared to those collected from wildtype mice (Fig. 2b) . The average diameters of the organoids derived from Nlrc3 −/− mice were significantly increased compared to the average diameters of the organoids from wildtype mice ( Fig. 2b) . Expression of the stemcell marker Lgr5 in the colon tissue was similar in wildtype and Nlrc3 −/− mice (Extended Data Fig. 4c ), suggesting that the differences in the number and size of intestinal organoids was due to differential colonyforming capacity rather than differences in the numbers of starting intestinal stem cells. To investi gate the effect of NLRC3 on cell proliferation more directly, we overex pressed NLRC3 in the human colon cell line HCT116 and found that these cells exhibited reduced levels of proliferation compared to cells expressing a control (GFP) protein ( Fig. 2c ). Furthermore, primary Nlrc3 −/− fibroblasts proliferated more rapidly than wildtype fibro blasts ( Fig. 2d) .
Cellular proliferation can also be achieved when growth factors, nutrients and cellular energy activate metabolic pathways via the kinase mTOR 16 . We found increased phosphorylation levels of S6 kinase, 4EBP1 and AKT at Ser473, the downstream targets of mTOR, in the colon tissue of Nlrc3 −/− mice compared to wildtype mice at day 14 ( Fig. 3a, b ). Increased phosphorylation of these mTOR targets was also observed in Nlrc3 −/− organoids compared to wildtype organoids ( Fig. 3c, d ). However, we found no difference in the expression of genes involved in the Wnt signalling pathway, including Wnt1, Ctnnb1, Lef1, Tcf4, Tcf7 and Axin2 (Extended Data Fig. 4c ). The extent of nuclear localization of β catenin was also similar between wildtype and Nlrc3 −/− mice (Extended Data Fig. 4d ). Dysregulation of the mTOR signalling pathways in Nlrc3 −/− mice occurred very early, 8 days after injection of azoxymethane, whereas no difference in the production of inflammatory cytokines and mediators and phosphorylation of Iκ Bα was observed at this time point (Extended Data Fig. 5, a-c) . Moreover, the differential AKT-mTOR signalling observed at this time point was not caused by differences in the relative levels of immune cells recruited to the colon (Extended Data Fig. 3d ). These data suggest that the dysregulated mTOR signalling observed at an earlier time point may lead to increased NFκ B signalling at a later time point.
Phosphorylation and activation of mTOR is driven by a number of upstream signalling proteins in the PI3K-AKT-mTOR pathway. Phosphorylation of AKT at the Thr308 site by the kinase PDK1 allows AKT to activate mTOR [17] [18] [19] . To examine whether NLRC3 directly affects the apical molecules in the PI3K-AKT-mTOR pathway, we first investigated the phosphorylation status of AKT at the Thr308 site. We observed elevated phosphorylation of AKT at Thr308 in the colon tissue of Nlrc3 −/− mice compared to wildtype mice at day 14 (Fig. 3e ). Increased levels of AKT phosphorylation in colon tissue were observed predominately in epithelial cells and, to a lesser extent, in infiltrating cells (Fig. 3f) . Similarly, increased phosphorylation of AKT at Thr308 was observed in Nlrc3 −/− organoids treated with IGF1 compared to wildtype controls (Fig. 3g, h ). We further observed increased activation of PDK1 in the colon tissue of Nlrc3 −/− mice treated with azoxymethane and DSS compared to wildtype mice (Fig. 3e ). In addition, elevated degree of phosphorylation of AKT at Thr308 and of 4EBP1 were observed in the colon of Nlrc3 +/− heterozygous mice compared to littermate wildtype mice at day 14, although this increase was smaller than that observed in littermate Nlrc3 −/− homozygous mice (Extended Data Fig. 6a ). The genedosedependent effect of NLRC3 on the suppression of the mTOR signalling pathways is reminiscent of the genedosedependent effect of NLRC3 on the suppression of tumorigenesis (Fig. 1g) .
Activated mTOR is phosphorylated and migrates to lysosomal and late endosomal membranes 20, 21 . We observed increased phospho rylation of mTOR in the colon tissue of Nlrc3 −/− mice (Fig. 3e ). We also found an increased colocalization frequency between mTOR and LAMP1 puncta in IGF1treated primary Nlrc3 −/− fibroblasts compared to IGF1treated primary wildtype fibroblasts (Fig. 4a ). Increased mTOR signalling was observed in Nlrc3 −/− fibroblasts or wildtype fibroblasts treated with short interfering RNAs (siRNAs) against Nlrc3 compared to their corresponding controls (Extended Data Figs 6b-e, 7a-d).
We further investigated whether NLRC3 is able to restrict prolife ration in a spontaneous mouse model of colon cancer. We crossed the mouse line containing a heterozygous mutation in the gene encoding adenomatous polyposis coli (Apc Min/+ ) with Nlrc3 −/− mice and found that Apc Min/+ Nlrc3 −/− mice had a higher tumour burden than Apc Min/+ control mice (Extended Data Fig. 8a ). Of the Apc Min/+ Nlrc3 −/− mice, 40% developed hyperplasia (compared to 0% in the littermate control group) and Apc Min/+ Nlrc3 −/− mice exhibited increased damage in the colon (Extended Data Fig. 8b, c) . Notably, we observed increased number of Ki67 + proliferative cells and cells positive for phospho rylated S6 kinase in the colon of Apc Min/+ Nlrc3 −/− mice compared to Apc Min/+ mice (Extended Data Fig. 8c ). Moreover, the capacity of Apc Min/+ Nlrc3 −/− intestinal stem cells to proliferate into organoids was greater than that of Apc Min/+ intestinal stem cells (Extended Data Fig. 8d ). Treatment with the PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin impaired the ability of intestinal stem cells to proliferate into organoids in both strains (Extended Data Fig. 8d ). Treatment of the Apc Min/+ mice and Apc Min/+ Nlrc3 −/− mice with the PI3K-mTOR inhibitor NVPBEZ235 reduced the tumour burden and phosphorylation of S6 kinase in the tumours and enterocytes of Apc Min/+ Nlrc3 −/− mice to a level observed in treated Apc Min/+ mice (Fig. 4b, c) . Collectively, these data suggest that NLRC3 restricts cellular proliferation via the PI3K-mTOR axis during colon tumorigenesis.
Following generation of inositol phospholipids by activated PI3Ks, AKT is recruited to the cell membrane where it undergoes a conformational change and is phosphorylated at Thr308 by PDK1 (refs 17-19) . Coimmunoprecipitation assays showed that NLRC3 weakly interacted with PDK1 and did not interact with AKT ( Fig. 4d ). Instead, we found that NLRC3 coimmunoprecipitated with p85 subunits of PI3K (Fig. 4d ). In addition, we observed increased levels of interaction between the p85 and p110α subunits of PI3K in Nlrc3 −/− primary fibroblasts or mouse bonemarrowderived macrophages (BMDMs) (Extended Data Fig. 9a, b) . We also observed a higher level of phosphorylation and activation of p85 PI3K in the colon tissue of Nlrc3 −/− mice treated with azoxymethane and DSS compared to wild type mice (Fig. 4e) . These data provide evidence to suggest that NLRC3 disrupts an association between the PI3K p85 and p110α subunits and reduces the activity of PI3K p85 itself. Deletion of the CARD, NACHT or LRR domain of NLRC3 impaired the ability of NLRC3 to interact with either the p85 or the p110α subunit of PI3K (Extended Data Fig. 9c-g) . Reconstitution of NLRC3 in Nlrc3 −/− fibroblasts reduced the degree of phosphorylation of AKT Thr308 and other downstream molecules to levels similar to those seen in wildtype fibroblasts upon stimulation with IGF1 ( Fig. 4f ).
In addition to growth factor receptors, activation of TLR4 can engage the PI3K-AKT-mTOR pathway [22] [23] [24] . We observed increased activation of the mTOR signalling pathways in lipopolysaccharide (LPS)treated primary Nlrc3 −/− BMDMs compared to LPStreated wildtype BMDMs (Extended Data Fig. 10a,b ). We further confirmed our findings in an independently generated line of NLRC3deficient mice that we term Nlrc3 ld/ld mice (NLRC3 large deletion, data not shown; see Methods). Collectively these findings identify NLRC3 as an inhibitory sensor of the PI3K-AKT-mTOR pathway, mediating protection against tumorigenesis in colorectal cancer (Extended Data Fig. 10c ).
NLRC3 does not act solely to protect against cancer. A previous study has shown that expression of NLRC3 is downregulated in patients with the autoimmune disease Wegener's granulomatosis 25 . Moreover, a lossoffunction mutation in the gene encoding the NLRC3like protein in zebrafish results in systemic inflammation 26 . These findings collectively provide evidence to support the crossspecies functionality of NLRC3. Whether NLRC3 needs to be bound to a specific ligand or is engaged in the activation of its regulatory function in a ligand independent manner remains to be explored. 
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Mice. Wildtype (C57BL/6) and Nlrc3 −/− mice were bred and maintained under specific pathogenfree conditions at St. Jude Children's Research Hospital. To generate the Nlrc3 −/− mice, exons 2 and 3 of the gene encoding NLRC3 (2.5 kb) were excised, which resulted in deletion of 661 amino acids encoding the Nterminal caspaserecruitment domain (also known as CARD) and the central nucleotidebinding domain (also known as NACHT) of NLRC3. Splicing of exon 1 and exon 4 led to a frameshift, generating a premature stop codon (Extended Data Fig. 1c ). The targeting vector ROS1HR was linearized and transfected into embryonic stem (ES) cells. Cells positive for the targeting vector were selected by resistance to 200 μ g ml −1 of G418 and further screened for 5′ and 3′ homologous recombination. ES cell clones with the correct targeting events were used for blas tocysts injection. CMV-Cre mice were used to delete the conditional floxed Nlrc3 allele to generate the Nlrc3 −/− mice. B6.129P2Lyz2 tm1(cre)Ifo /J (004781, The Jackson Laboratory), B6.CgTg(Vav1icre)A2Kio/J (008610, The Jackson Laboratory) and B6.CgTg(Vilcre)997Gum/J mice (004586, The Jackson Laboratory) were used to delete the conditional floxed Nlrc3 allele in a celltypespecific manner. Expression of NLRC3 in wildtype and Nlrc3 −/− mice were confirmed by genomic PCR ampli fication (Extended Data Fig. 1c ). Nlrc3 −/− mice were backcrossed to C57BL/6 for nine generations.
Nlrc3 ld/ld (Nlrc3 large deletion) mice were generated by injection of two single guide RNAs (Nlrc3Guide01: 3′ATTCCCAGGTCGTCTTAGGC5′; 125 ng μ l −1 ) and Nlrc3Guide02: 3′AGTGGAACAGCACAGTTCGC5′; 125 ng μ l −1 ), designed to introduce DNA doublestrand breaks into intron 1 and intron 3 of the Nlrc3 gene, together with a codonoptimized Cas9 mRNA transcript (50 ng μ l −1 ) into the cytoplasm of the pronuclear stage C57BL/6J zygotes (Transgenic Core Unit, St. Jude Children's Research Hospital). Injected embryos were surgically transplanted into oviducts of pseudo pregnant CD1 females and newborn mice bearing the intron1tointron3 deletion (~ 3.8 kb) were identified by the amplification of a 1.1kb fragment using primers flanking the two break sites: Nlrc3F51: 3′AGAGTGGTGCCATCTTCTGC5′ and Nlrc3R32: 3′CTCAAGTCAGGGCAGCATGA5′. Sanger sequencing of the ~ 1.1kb amplicon confirmed proper deletion of the 3.8kb fragment containing exon 2 and 3. The sgRNAs and Cas9 mRNA transcript were designed and generated as described previously 27 . Potential offtarget sites were identified using CasOFFinder 28 , amplified by PCR and sequenced. No offtarget site cleavage was observed. Two founder mice were used to establish the mouse lines. Animal study protocols were approved by the St. Jude Children's Research Hospital Committee on Use and Care of Animals. Azoxymethane-DSS model of colorectal tumorigenesis. Male and female mice were used at the age of six weeks. For cohousing experiments, wildtype and Nlrc3 −/− mice were cohoused for three weeks and separated before injection of azoxymethane. We also performed experiments whereby wildtype and Nlrc3 −/− mice were cohoused for three weeks before injection of azoxymethane and remained cohoused over the course of the experiments. In both cases, the results did not differ. Mice were injected intraperitoneally with 10 mg of azoxymethane (A5486, Sigma) per kg body weight, according to previously established protocols 7, 29 . After 5 days, 2% DSS (9011181, Affymetrix eBioscience) was given in the drinking water for 6 days followed by regular drinking water for 2 weeks. This cycle was repeated twice more with 1.5% DSS and mice were killed on day 80 (Extended Data Fig. 1a ). For day 8 samples, mice were injected with azoxymethane, and after 5 days, fed with 2% DSS for 3 days before being killed. For Day 14 samples, mice were injected with azoxymethane, and after 5 days, fed with 2% DSS for 6 days. Mice were then fed with regular water for 3 days and collected. Bonemarrow chimaera studies were performed as described previously 7 . No randomization or blinding was performed. Apc Min model of colorectal tumorigenesis. C57BL/6JApc Min/+ /J mice (002020, The Jackson Laboratory) were crossed with Nlrc3 −/− mice. Littermate Apc Min/+ and Apc Min/+ Nlrc3 −/− mice were administered with either 40 mg kg −1 body weight of the dual inhibitor of PI3K and mTOR, NVPBEZ235 (N4288, LC Laboratories) dissolved in 10% (v/v) 1methyl2pyrrolidone (328634, Sigma) plus 90% (v/v) polyethylene glycol 300 (90878, Sigma) or the control vehicle 10% (v/v) 1methyl2pyrrolidone plus 90% (v/v) polyethylene glycol 300 by daily oral gavage for 40 days from 6 weeks of age. Histology and microscopy analysis. Colons were rolled into a 'Swiss roll' and fixed in 10% formalin, processed and embedded in paraffin by standard techniques. Longitudinal sections of 5 μ m were stained with haematoxylin and eosin and examined by a pathologist blinded to the experimental groups. Colitis scores were assigned based on inflammation, ulceration, hyperplasia and the extent or severity of damage. Severity scores for inflammation were assigned as follows: 0 = normal (within normal limits); 2 = minimal (mixed inflammation, small, focal or widely separated, limited to lamina propria); 15 = mild (multifocal mixed inflammation, often extending into submucosa); 40 = moderate (large multifocal lesions within mixed inflammation involving mucosa and submucosa); 80 = marked (extensive mixed inflammation with oedema and erosions; 100 = severe (diffuse inflam mation with transmural lesions and multiple ulcers). Scores for ulceration were assigned as follows: 0 = normal (none); 2 = minimal (only one small focus of ulceration involving fewer than 5 crypts); 15 = mild (a few small ulcers up to 5 crypts); 40 = moderate (multifocal ulcers up to 10 crypts); 80 = marked (multifocal to coalescing ulcers involving more than 10 crypts each); 100 = severe (extensive to diffuse with multiple ulcers covering more than 20 crypts each). Scores of hyperplasia were assigned as follows: 0 = normal; 2 = minimal (some areas with crypts elongated and increased mitoses); 15 = mild (multifocal areas with crypts elongated up to twice the normal thickness, normal goblet cells present); 40 = moderate (extensive areas with crypts up to twice the normal thickness, reduced goblet cells); 80 = marked (mucosa over twice the normal thickness, hyperchromatic epithelium, reduced or rare goblet cells, possibly foci of arborization); 100 = severe (mucosa twice the normal thickness, marked hyperchromasia, crowding or stacking, absence of goblet cells, high mitotic index and arborization). Scores of extent were assigned as follows: 0 = normal (rare or inconspicuous lesions); 2 = minimal (less than 5% involvement); 15 = mild (multifocal but conspicuous lesions, 5-10% involvement); 40 = moderate (multifocal, prominent lesions, 10-50% involvement); 80 = marked (coalescing to extensive lesions or areas of inflammation with some loss of structure, 50-90% involvement); 100 = severe (diffuse lesion with effacement of normal structure, over 90% involvement). The proliferating cells in the intestinal epithelium were detected by immunoperoxidase staining for Ki67 and PCNA. The immunohis tochemistry antibodies used were: Ki67 (NBP140684, Novus), PCNA (M0879, DAKO), β catenin (610154, BD), PAKT Ser473 (4060, Cell Signaling), and PS6 Ribosomal Protein Ser235236 (4858, Cell Signaling). Tissues were counterstained with haematoxylin. The number of Ki67 + or PCNA + cells per crypt in each animal was counted (at least 18-20 crypts per mouse). Cell culture and stimulation of cells. Pinna of adult wildtype and Nlrc3 −/− mice were minced and digested with 100 mg ml −1 collagenase type IV (LS004188, Worthlington Biochemical Corporation) for 3 h, followed by filtration through 70μ m strainers to obtain fibroblasts. Cells were cultured in 50% FBS (TMS013B, Millipore) in DMEM (11995073, ThermoFisher Scientific) supplemented with HEPES (15630080, ThermoFisher Scientific), 1% penicillin and streptomycin (15070063, ThermoFisher Scientific), lglutamine (25030, ThermoFisher Scientific), sodium pyruvate (11360, ThermoFisher Scientific), nonessential amino acids (11140, ThermoFisher Scientific), and β mercaptoethanol (21985023, ThermoFisher Scientific) for the first 3-4 days. Cells were subcultured in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin. All primary fibroblasts were used before reaching the sixth passage. Fibroblasts were seeded onto sixwell plates at a density of 2 × 10 5 cells per well. Cells were deprived of serum for 36 h and further incubated in PBS for 1 h. Cells were then stimulated with 50 ng ml −1 of recombinant murine IGF1 (25019, Peprotech) for the indicated time.
BMDMs were cultured as described previously 30 . BMDMs were stimulated with 500 ng ml −1 ultrapure LPS from Salmonella minnesota R595 (tlrlsmlps, InvivoGen) for the indicated time. The human colorectal carcinoma HCT116 cell line (ATCC#CCL247, American Type Culture Collection) was cultured in McCoy's 5A medium (16600082, ThermoFisher Scientific) supplemented with 10% FBS and 1% penicillin and streptomycin. The embryonic kidney epithelial cell line HEK293T (ATCC#3216, American Type Culture Collection) and L929 cell line (ATCC#CRL2648, American Type Culture Collection) were cultured in DMEM supplemented with 10% FBS. All cell lines were maintained at 37 °C with 5% CO 2 . Colon organoid culture. Mouse colon stem cells were cultured using IntestiCult organoid growth medium according to the manufacturer's instructions (06005, STEMCELL Technologies). The whole colon was removed from untreated wild type and Nlrc3 −/− mice and rinsed with cold PBS. The colon was cut into 2mm segments and washed 20 times with cold PBS. Colonic segments were incubated in Gentle Cell Dissociation Reagent (07174, STEMCELL Technologies), rotated at 350g for 15 min at room temperature, followed by resuspension in PBS supplemented with 0.1% BSA (A6003, Sigma). Dissociated colonic crypts were filtered through 70μ m strainers. Dissociated colonic crypts were resuspended in DMEM/ F12 medium with 15 mM HEPES (36254, STEMCELL Technologies), counted and resuspended in Intesticult organoid growth medium and Matrigel (356230, Corning) in a 1:1 ratio. Cells were plated in 24well culture plates (3738, Corning). Intesticult organoid growth medium were added to the cell culture plates to immerse the matrix composed of Intesticult organoid growth medium and Matrigel. For inhi bition studies, 50 μ M of LY294002 (440202, Millipore) or 10 μ g ml −1 rapamycin (553210, Sigma) was added to the Intesticult organoid growth medium. Proliferation assay. Cell proliferation was measured using the WST1 reagent (05015944001, Roche). Primary ear fibroblasts or HCT116 cells were plated at a density of 5,000 cells per well in 96well tissue culture plates and incubated 
